The rising global prevalence of inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, underscores the need to examine current and future IBD care costs. Direct health care expenses, including ambulatory visits, hospitalizations, and medications, are substantial, averaging $9,000 to $12,000 per person annually in high-income regions. However, these estimates do not fully account for factors such as disease severity, accessibility, and variability in health care infrastructure among regions. Indirect costs, predominantly stemming from loss in productivity due to absenteeism, presenteeism, and other intangible costs, further contribute to the financial burden of IBD. Despite efforts to quantify indirect costs, many aspects remain poorly understood, leading to an underestimation of their actual impact. Challenges to achieving cost sustainability include disparities in access, treatment affordability, and the absence of standardized cost-effective care guidelines. Strategies for making IBD care sustainable include early implementation of biologic therapies, focusing on cost-effectiveness in settings with limited resources, and promoting the uptake of biosimilars to reduce direct costs. Multidisciplinary care teams leveraging technology and patient-reported outcomes also hold promise in reducing both direct and indirect costs associated with IBD. Addressing the increasing financial burden of IBD requires a comprehensive approach that tackles disparities, enhances access to cost-effective therapeutics, and promotes collaborative efforts across health care systems. Embracing innovative strategies can pave the way for personalized, cost-effective care accessible to all individuals with IBD, ensuring better outcomes and sustainability.

中文翻译：

---

炎症性肠病护理的成本——如何使其可持续


克罗恩病和溃疡性结肠炎等炎症性肠病 (IBD) 的全球患病率不断上升，凸显了检查当前和未来 IBD 护理成本的必要性。直接医疗保健费用（包括门诊、住院和药物治疗）数额巨大，在高收入地区，每人每年平均花费 9,000 至 12,000 美元。然而，这些估计并未充分考虑疾病严重程度、可及性以及各地区医疗保健基础设施的差异等因素。间接成本主要是由于缺勤、出勤和其他无形成本造成的生产力损失，进一步加重了 IBD 的财务负担。尽管努力量化间接成本，但许多方面仍然知之甚少，导致其实际影响被低估。实现成本可持续性的挑战包括可及性、治疗负担能力的差异以及缺乏标准化的具有成本效益的护理指南。使 IBD 护理可持续的策略包括尽早实施生物疗法、注重资源有限环境中的成本效益，以及促进生物仿制药的采用以降低直接成本。利用技术和患者报告结果的多学科护理团队也有望降低与 IBD 相关的直接和间接成本。解决 IBD 日益增加的财务负担需要采取全面的方法来解决差异，增加获得具有成本效益的治疗的机会，并促进整个医疗保健系统的协作。采用创新策略可以为所有 IBD 患者提供个性化、具有成本效益的护理铺平道路，确保更好的结果和可持续性。